Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Oncotarget|May 7, 2015
Differential gene expression in human abdominal aortic aneurysm and aortic occlusive diseaseErik Biros, Gabor Gäbel, Corey S Moran, et al.Circulation|July 7, 2005
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary diseaseMarcello Tonelli, Chris Isles, Timothy Craven, et al.Journal of the American Heart Association|February 18, 2022
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID StudyMalcolm West, Adrienne Kirby, Ralph A Stewart, et al.Journal of the American Heart Association|June 29, 2022
B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart DiseaseRalph A H Stewart, Adrienne Kirby, Harvey D White, et al.Atherosclerosis|February 18, 2014
Differential gene expression in the proximal neck of human abdominal aortic aneurysmErik Biros, Corey S Moran, Catherine M Rush, et al.BMJ Open|May 6, 2026
Development of a core screening, assessment and outcome set for cancer prehabilitation: an international Delphi consensus study protocolThomas Parkington, Liam John Humphreys, Malcolm West, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|November 19, 2019
Low thoracic muscle radiation attenuation is associated with postoperative pneumonia following partial hepatectomy for colorectal metastasisGregory van der Kroft, David P J van Dijk, Sander S Rensen, et al.F1000Research|October 18, 2022
The Wessex Fit-4-Cancer Surgery Trial (WesFit): a protocol for a factorial-design, pragmatic randomised-controlled trial investigating the effects of a multi-modal prehabilitation programme in patients undergoing elective major intra-cavity cancer surgeryMalcolm West, Andrew Bates, Chloe Grimmett, et al.Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.International Journal of Cardiology|August 31, 2015
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker studyAndrew M Tonkin, Stefan Blankenberg, Adrienne Kirby, et al.Pageof 5